Smart dosing: tailoring cancer drug levels could extend life for colorectal patients
NCT ID NCT06642844
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This Phase 3 trial tests whether adjusting the dose of bevacizumab based on each patient's drug levels can better control metastatic colorectal cancer. About 244 people will receive either standard or personalized dosing alongside chemotherapy. The main goal is to see if personalized dosing delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE/METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BORG
RECRUITINGBesançon, France
Contact
-
Caroline Petorin
NOT_YET_RECRUITINGClermont-Ferrand, France
-
David Tougeron
RECRUITINGPoitiers, France
Contact
-
Ducreux
NOT_YET_RECRUITINGGustave Roussy, France
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin)
What this could lead to
If successful, this could show that tailoring bevacizumab dose to individual drug levels improves how long the cancer is kept under control.
What could go wrong
This is a Phase 3 trial, but personalized dosing adds complexity and may not improve outcomes over standard dosing. Side effects of bevacizumab, like bleeding or high blood pressure, remain a risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.